Successful chemotherapy in a male patient with malignant lymphoma and Leber's hereditary optic neuropathy (LHON)

American Journal of Hematology

Volumn 72, Issue 4, 2003, Pages 263-266

  Zanssen, Stefanie ^a,b   Buse, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Columbia University ^*  (United States)

Author keywords

Apoptosis; Chemotherapy; LHON; Lymphoma; Mitochondrial disorders; mtDNA

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIRUBICIN; MAFOSFAMIDE; MITOCHONDRIAL DNA; PREDNISONE; VINCRISTINE;

ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DETERMINATION; FLOW CYTOMETRY; GENOME; HEREDITARY OPTIC ATROPHY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LYMPHOMA; MALE; MISSENSE MUTATION; MITOCHONDRIAL GENETICS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; OPTIC NERVE; PRIORITY JOURNAL; RESPIRATORY CHAIN; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DNA, MITOCHONDRIAL; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MALE; OPTIC ATROPHY, HEREDITARY, LEBER; PREDNISONE; REMISSION INDUCTION; VINCRISTINE;

EID: 0037382619     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10301     Document Type: Article

References (25)

1. DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. Am J Med Genet 2001;106:18-26.
2. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1999;1411:201-205.
3. Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, Hidaka T, Toshima H. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 1993;195:945-951.
4. Takeda N. Cardiomyopathies and mitochondrial DNA mutations. Mol Cell Biochem 1997;176:287-290.
5. Agarwal RP, Olivero OA. Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3′-azido-2′,3′-dideoxythymidine. Mutat Res 1997;390:223-231.
6. Hentosh P, Tibudan M. 2-Chloro-2′-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol 1997;51:613-629.
7. Wallace DC, Brown MD, Melov S, Graham B, Lott M. Mitochondrial biology, degenerative diseases and aging. Biofactors 1998;7:187-190.
8. Chinnery PF, Howell N, Andrews RM, Turnbull DM. Clinical mitochondrial genetics. J Med Genet 1999;36:425-436.
9. Singh G, Lott MT, Wallace DC. A mitochondrial DNA mutation as a cause of Leber's hereditary optic neuropathy. N Engl J Med 1989;320:1300-1305.
10. Chalmers RM, Schapira AH. Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Biochim Biophys Acta 1999;1410:147-158.
11. Kerrison JB, Newman NJ. Clinical spectrum of Leber's hereditary optic neuropathy. Clin Neurosci 1997;4:295-301.
12. Nikoskelainen E, Asola M, Kalimo H, Savontaus ML, Majander A. Benzodiazepine sensitivity in Leber's hereditary optic neuroretinopathy [letter]. Lancet 1992;340:1223-1224.
13. Burde RM, Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1993;116:759-764.
14. Howell N. Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vision Res 1998;38:1495-1504.
15. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER, Veerman AJ. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood, Br J Cancer 1991;64:469-474.
16. Wallace DC, Zheng XX, Lott MT, Shoffner JM, Hodge JA, Kelley RI, Epstein CM, Hopkins LC. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988;55:601-610.
17. Merkelbach S, Gehlen J, Handt S, Fuzesi L. Novel enzyme immunoassay and optimized DNA extraction for the detection of polymerasechain-reaction-amplified viral DNA from paraffin-embedded tissue. Am J Pathol 1997;150:1537-1546.
18. Johns DR, Neufeld MJ. Pitfalls in the molecular genetic diagnosis of Leber hereditary optic neuropathy (LHON). Am J Hum Genet 1993;53:916-920.
19. Danielson SR, Wong A, Catelli V, Martinuzzi A, Schapira AHV, Cortopassi GA. Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to FAS-induced apoptosis. J Biol Chem 2002;277:5810-5815
20. Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999;18:6641-6646.
21. Carelli V, Ghelli A, Ratta M, Bacchilega E, Sangiorgi S, Mancini R, Leuzzi V, Cortelli P, Montagna P, Lugaresi E, Degli Esposti M. Leber's hereditary optic neuropathy: biochemical effect of 11778/ND4 and 3460/ND1 mutations and correlation with the mitochondrial genotype. Neurology 1997;48:1623-1632.
22. Hofhaus G, Johns DR, Hurko O, Attardi G, Chomyn A. Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy. J Biol Chem 1996;271:13155-13161.
23. Larsson NG, Andersen O, Holme E, Oldfors A, Wahlstrom J. Leber's hereditary optic neuropathy and complex I deficiency in muscle. Ann Neurol 1991;30:701-708.
24. Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M. Electron transfer properties of NADH:ubiquinone reductase in the ND 1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON). FEBS Lett 1991;292:289-292.
25. Yen MY, Lee JF, Liu JH, Wei YH. Energy charge is not decreased in lymphocytes of patients with Leber's hereditary optic neuropathy with the 11,778 mutation. J Neuroophthalmol 1998;18:84-85.